| 28th May 2024 12:01 pm |
EQS |
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK |
| 23rd May 2024 12:01 pm |
EQS |
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update |
| 24th Apr 2024 12:08 pm |
EQS |
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update |
| 24th Apr 2024 12:04 pm |
EQS |
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK |
| 24th Apr 2024 12:01 pm |
EQS |
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer |
| 18th Apr 2024 12:01 pm |
EQS |
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 |
| 16th Apr 2024 12:02 pm |
EQS |
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines |
| 4th Apr 2024 12:02 pm |
EQS |
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK |
| 5th Jan 2024 12:02 pm |
EQS |
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform |
| 19th Dec 2023 2:24 pm |
EQS |
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE |
| 14th Nov 2023 12:02 pm |
EQS |
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update |
| 1st Nov 2023 12:02 pm |
EQS |
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK |
| 28th Sep 2023 12:02 pm |
EQS |
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany |
| 12th Sep 2023 12:01 pm |
EQS |
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage |
| 17th Aug 2023 12:01 pm |
EQS |
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update |
| 1st Aug 2023 12:01 pm |
EQS |
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK |
| 14th Jul 2023 12:01 pm |
EQS |
CureVac Announces Update to the Management Team |
| 13th Jul 2023 12:01 pm |
EQS |
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights |
| 20th Jun 2023 12:06 pm |
EQS |
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma |
| 20th Jun 2023 12:01 pm |
EQS |
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board |
| 19th Jun 2023 4:31 pm |
EQS |
CureVac Announces Voting Results of General Meeting |
| 30th May 2023 12:01 pm |
EQS |
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update |
| 19th May 2023 12:01 pm |
EQS |
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech |
| 8th May 2023 12:01 pm |
EQS |
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK |
| 25th Apr 2023 12:01 pm |
EQS |
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update |
| 18th Apr 2023 12:01 pm |
EQS |
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 |
| 28th Mar 2023 9:06 pm |
EQS |
CureVac Announces Voting Results of Extraordinary General Meeting |
| 10th Feb 2023 9:05 pm |
EQS |
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares |
| 8th Feb 2023 1:04 am |
EQS |
CureVac Announces Pricing of Upsized Public Offering of Common Shares |
| 6th Feb 2023 9:06 pm |
EQS |
CureVac Announces Proposed Public Offering of Common Shares |
| 1st Feb 2023 12:00 pm |
EQS |
CureVac Welcomes Myriam Mendila as New Chief Development Officer |
| 31st Jan 2023 1:13 pm |
EQS |
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® |
| 30th Jan 2023 12:02 pm |
EQS |
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs |
| 9th Jan 2023 12:00 pm |
EQS |
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 |
| 6th Jan 2023 12:01 pm |
EQS |
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs |
| 14th Dec 2022 9:05 pm |
EQS |
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program |
| 16th Nov 2022 12:00 pm |
EQS |
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update |
| 11th Nov 2022 12:00 pm |
EQS |
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 |
| 10th Nov 2022 12:00 pm |
EQS |
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022 |
| 18th Aug 2022 12:06 pm |
EQS |
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update |
